Beta-blockers can reduces risk of osteoporotic fracture by around 50 per cent in men and women, say Australian researchers.
The beta-blockers, a class of drugs that reduce the effects of stress hormones, are widely used to treat heart problems, hypertension and some anxiety disorders.
PhD student Shuman Yang and Professor Tuan Nguyen from Sydney’s Garvan Institute of Medical Research used data collected from the long-running Dubbo Osteoporosis Epidemiology Study to demonstrate that people on beta-blockers have lower risk of fracture and better bone density. They also warn moving from the beta-blockers as the preferred line of treatment for heart problems could leave bones without the much-needed protection. Their findings are now online in the international journal, Bone.
“The thing that spurred this study was a remarkable finding from a research group at Columbia University a few years ago which showed that mice treated with beta-blockers have increased bone mass,” said project leader Professor Nguyen.
“That was very significant, as it showed that the sympathetic nervous system has an effect on bone.”
“So we set out to test the hypothesis that ‘if mice treated with beta blockers have increased bone mass, and we know that increased bone mass is associated with reduced fracture risk, then people on beta blockers should have reduced fracture risk’.”
“We found that indeed it was the case – beta-blockers reduced the risk of fracture by about 50 per cent in men and women, which is dramatic. Drugs used specifically for treating osteoporosis also reduce fracture by around the same magnitude.”